187342-24-1Relevant academic research and scientific papers
Synthesis and Preclinical Evaluation of an 18F-Labeled Synaptic Vesicle Glycoprotein 2A PET Imaging Probe: [18F]SynVesT-2
Baum, Evan,Cai, Zhengxin,Carson, Richard E.,Finnema, Sjoerd J.,Holden, Daniel,Huang, Yiyun,Labaree, David C.,Li, Songye,Lin, Shu-Fei,Lindemann, Marcel,Nabulsi, Nabeel,Pracitto, Richard,Ropchan, Jim,Shirali, Anupama,Toyonaga, Takuya,Wu, Xiaoai,Zhang, Wenjie
, p. 592 - 603 (2020/03/06)
Synaptic vesicle glycoprotein 2A (SV2A) is a 12-pass transmembrane glycoprotein ubiquitously expressed in presynaptic vesicles. In vivo imaging of SV2A using PET has potential applications in the diagnosis and prognosis of a variety of neuropsychiatric diseases, e.g., Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, autism, epilepsy, stroke, traumatic brain injury, post-traumatic stress disorder, depression, etc. Herein, we report the synthesis and evaluation of a new 18F-labeled SV2A PET imaging probe, [18F]SynVesT-2, which possesses fast in vivo binding kinetics and high specific binding signals in non-human primate brain.
RADIOLABELED PHARMACEUTICALS AND METHODS OF MAKING AND USING SAME
-
Page/Page column 32, (2018/09/12)
In one aspect, the invention comprises compounds that bind to the synaptic vesicle protein SV2A and that can be useful as radiotracers for positron emission tomography. In another aspect, the invention comprises methods of imaging the brain, measuring synaptic density or diagnosing neurological diseases such as Alzheimer's disease, psychiatric disorders such as depression, and metabolic disorders such as diabetes comprising detecting the compounds of the invention by positron emission tomography (PET).
